ERAS-007, which is an effective ERK1 / 2 inhibitor, will be tested in combination with encorafenib and cetuximab in BRAF V600E-mutant metastatic colorectal cancer (mCRC) patients
HERKULES-3 CRC Phase 1b / 2 test results expected at H2 2021
SAN DIEGO, September 08, 2021 (GLOBE NEWSWIRE) – Erasca, Inc. Cancer, today announced a partnership agreement with clinical trials with Pfizer Inc. (NYSE: PFE) for BRAF inhibitor encorafenib (BRAFTOVI®).
This agreement will support the evidence-based study confirming ERAS-007, oral ERK1 / 2 inhibitor, as well as encorafenib and EGFR inhibitor cetuximab for the treatment of patients with BRAF V600E-mutant mCRC. This meeting will be investigated as part of the Phase 1b / 2 HERKULES-3 case expected to begin in the second half of 2021. Erasca will support the study, and Pfizer will provide encorafenib. The two companies will form a Joint Development Committee to evaluate the results of clinical trials.
“We are excited to work with Pfizer to explore this promising combination of color cancer,” said Jonathan E. Lim, MD, Erasca chairman, CEO and co-founder. “The signing of the MAPK is vigorous in patients with genetic mutations in the BRAF V600E, who often have a negative outlook. Combining a rising EGFR ban, a BRAF intermediate barrier, and a lower ERK barrier fit Erasca’s cancer clearance strategies and has the potential to reduce road performance, providing the possibility of treatment to close the RAS / MAPK pathway with this tumor. “
Worldwide, about 1.8 million CRC cases are diagnosed annually, and changes in BRAF V600E occur in about 10% of patients. The combination of encorafenib and cetuximab was approved in April 2020 for previously treated patients with BRAF V600E-mutant mCRC. This combination showed a general improvement in survival compared to the chemotherapy control arm; however, only 20% of patients received a targeted response, and non-progressive survival was approximately four months. Thus, the emergence of resistance is a major barrier to treatment for long-term clinical benefit. Erasca is investigating whether the inhibition of ERK and ERAS-007 combined with encorafenib as well as cetuximab may reduce the occurrence of resistance and improve the therapeutic efficacy for patients of BRAF V600E-mutant mCRC.
Approximately ERAS-007ERAS-007 is a highly advanced browser in the ERK1 / 2 group that is being investigated individually or in combination with various inhibitors that monitor the rising nodes of the MAPK path as part of a strategy la Erasca la MAPKlamp. The extracellular (ERK)-regulated cell kinases, ERK1 and ERK2, belong to the family of serine-threonine kinases that regulate cell signaling and have the final component of the RAS / MAPK pathway. ERAS-007 is being investigated in a list of four HERKULES clinical trials that offer a wide range of tumors and includes monotherapy and combination with authorized and research agents, such as RTK, SHP2, RAS, RAF, and / or cell cycle inhibitors. HERKULES-1 is a Phase 1b / 2 clinical trial of ERAS-007 as a single agent and combined with the SHP2 inhibitor ERAS-601 (together, Erasca’s first MAPKlamp) with advanced advanced tumors. HERKULES-2 is a clinical Phase 1b / 2 clinical trial for ERAS-007 combined with different agents in patients with subcutaneous cancer. HERKULES-3 is a Phase 1b / 2 clinical trial of the ERAS-007 clinic combined with different agents in patients with colon cancer. HERKULES-4 is a Phase 1b / 2 clinical trial of the ERAS-007 clinic combined with different agents in patients with hematologic malignancies.
About Erasca In Erasca, our name is our mission: Eradicate cancer. We are a comprehensive oncology company that specializes in diagnosing, developing and marketing treatment options for patients with RAS / MAPK-led cancer. Our company has been co-founded by pioneers who are leading the way in oncology and RAS looking to create medical drugs and integrated approaches designed to close the RAS / MAPK cancer treatment pathway. We have compiled what we believe to be a deep RAS / MAPK pipeline in the industry. We believe that the expertise and experience of our team, will continue to be guided by our scientific advisory board which includes world-leading experts on the RAS / MAPK road, in a unique way that stops us from achieving our goal. powerful anti-cancer agent.
Awareness of anticipated statements Expectative statements are based on our current beliefs and expectations and include, but are not limited to: our expectations about the medical benefits of our product choice, including ERAS-007 and ERAS-601; our beliefs about market size and opportunities; and the planned development of our development pipeline, including medical development plans and trial dates for each HERKULES trial. True results may differ from those stated in this publication because of the risks and variations in our business, including, without limitation: our method of discovery and the development of nominees. product in line with our single goal of closing the RAS / MAPK path, novel and unproven method; Delays in our early development and treatment programs; our reliance on third parties for the production, research, and preliminary and clinical trials; the unintended negative consequences or inadequate success of our product selectors which may limit their growth, regulatory approval, and / or business, or may result in recollection or credit claims for the product; unpleasant results from medical studies or clinical trials; results from premature studies or preliminary clinical trials do not necessarily predict future outcomes; regulatory improvements in the United States and abroad; our ability to obtain and maintain intellectual property protection for product selectors and to secure our rights under intellectual property license; our ability to support our operational plans with our current funding, cash equity and investment; our ability to keep business operations intact ng due to the COVID-19 epidemic; and other risks described in our prio r filings by the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our quarterly Form 10-Q report and subsequent SEC films. You are warned not to place unreasonable expectations on these prospective statements, which speak only of the day here, and we have no obligation to refine such statements to show the events that are taking place or the circumstances that exist afterwards. the day here. All anticipated statements are fully justified by this cautionary statement, made under the protective provisions of the port of the Human Rights Reform Act of 1995.
Contact: Joyce AllaireLifeSci Advisors, [email protected]